抗结核新药早期杀菌活性研究方法专家共识

doi:10.3969/j.issn.1000-6621.2021.10.002

摘要/Abstract

摘要：

结核病疫情依然严峻,迫切需要抗结核新药。新药临床试验是新药研发的最重要阶段,早期杀菌活性(early bactericidal activity,EBA)研究是新型抗结核药物首次用于结核病患者治疗时进行的临床研究,也是单个抗结核药物和新的联合方案临床评价的关键。为了规范开展以及更好地推进我国抗结核新药研发进程,首都医科大学附属北京胸科医院和《中国防痨杂志》编辑委员会共同组织结核病临床研究和基础研究领域的专家,经反复讨论,撰写了《抗结核新药早期杀菌活性研究方法专家共识》,就抗结核新药EBA的意义、设计、实施,以及影响因素等内容进行阐述。

关键词: 结核, 药物评价, 早期杀菌活性, 总结性报告(主题)

Abstract:

The tuberculosis epidemic is still severe, and new anti-tuberculosis drugs are urgently needed. Clinical trials of new drugs are the most important stage of new drug development. Early bactericidal activity (EBA) is the first step in clinical study of new anti-tuberculosis drugs used in the treatment of tuberculosis patients, and it is also the key of clinical evaluation of the single anti-tuberculosis drug and a new regimen. In order to standardize and better promote the development of new anti-tuberculosis drugs in China, after repeated discussions by experts in the field of tuberculosis clinical and basic research organized by Beijing Chest Hospital affiliated to Capital Medical University and the Editorial Board of Chinese Journal of Antituberculosis, the Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs has been formulated on the significance, design, implementation, and influencing factors of the EBA study on the new anti-tuberculosis drugs.

Key words: Tuberculosis, Drug evaluation, Early bactericidal activity, Consensus development conferences as topic

首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 《中国防痨杂志》编辑委员会. 抗结核新药早期杀菌活性研究方法专家共识[J]. 中国防痨杂志, 2021, 43(10): 987-992. doi: 10.3969/j.issn.1000-6621.2021.10.002

Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute , Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 987-992. doi: 10.3969/j.issn.1000-6621.2021.10.002

参考文献 42

[1]	Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis, 1980, 121(6): 939-949. doi: 10.1164/arrd.1980.121.6.939. doi: 10.1164/arrd.1980.121.6.939
[2]	Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther, 2003, 1(1): 141-155. doi: 10.1586/14787210.1.1.141. doi: 10.1586/14787210.1.1.141 URL
[3]	Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med, 2003, 167(10): 1348-1354. doi: 10.1164/rccm.200210-1125OC. doi: 10.1164/rccm.200210-1125OC URL
[4]	Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb), 2008, 88 Suppl 1:S75-S83. doi: 10.1016/S1472-9792(08)70038-6. doi: 10.1016/S1472-9792(08)70038-6 URL
[5]	Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomized trial. Lancet, 2012, 380(9846): 986-993. doi: 10.1016/S0140-6736(12)61080-0. doi: 10.1016/S0140-6736(12)61080-0 URL
[6]	Dooley KE, Miyahara S, von Groote-Bidlingmaier F, et al. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. Am J Respir Crit Care Med, 2020, 201(11): 1416-1424. doi: 10.1164/rccm.201910-1960OC. doi: 10.1164/rccm.201910-1960OC URL
[7]	Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother, 2010, 54(8): 3402-3407. doi: 10.1128/AAC.01354-09. doi: 10.1128/AAC.01354-09 URL
[8]	Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405. doi: 10.1056/NEJMoa0808427. doi: 10.1056/NEJMoa0808427 URL
[9]	Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother, 2008, 52(8): 2831-2835. doi: 10.1128/AAC.01204-07. doi: 10.1128/AAC.01204-07 pmid: 18505852
[10]	Paramasivan CN, Herbert D, Umapathy KC, et al. Early bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide in pulmonary tuberculosis patients. Indian J Med Res, 1994, 100: 1-4. pmid: 7927544
[11]	Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother, 2000, 45(6): 859-870. doi: 10.1093/jac/45.6.859. doi: 10.1093/jac/45.6.859 URL
[12]	Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis, 2006, 10(6): 605-612. pmid: 16776446
[13]	Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis, 2010, 29(12): 1561-1565. doi: 10.1007/s10096-010-1043-7. doi: 10.1007/s10096-010-1043-7 URL
[14]	McAulay K, Saito K, Warrier T, et al. Differentially detectable Mycobacterium tuberculosis cells in sputum from treatment-naive subjects in Haiti and their proportionate increase after initiation of treatment. mBio, 2018, 9(6): e02192-18. doi: 10.1128/mBio.02192-18. doi: 10.1128/mBio.02192-18
[15]	Epstein MD, Schluger NW, Davidow AL, et al. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest, 1998, 113(2): 379-386. doi: 10.1378/chest.113.2.379. doi: 10.1378/chest.113.2.379 pmid: 9498955
[16]	Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis, 2010, 14(5): 560-570. pmid: 20392348
[17]	Pheiffer C, Carroll NM, Beyers N, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis, 2008, 12(7): 792-798. pmid: 18544206
[18]	Abe C, Hosojima S, Fukasawa Y, et al. Comparison of MB-Check,BACTEC, and egg-based media for recovery of mycobacteria. J Clin Microbiol, 1992, 30(4): 878-881. doi: 10.1128/jcm.30.4.878-881.1992. doi: 10.1128/jcm.30.4.878-881.1992 pmid: 1572974
[19]	Chew WK, Lasaitis RM, Schio FA, et al. Clinical evaluation of the mycobacteria growth indicator tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of mycobacterium species. J Med Microbiol, 1998, 47(9): 821-827. doi: 10.1099/00222615-47-9-821. doi: 10.1099/00222615-47-9-821 pmid: 9736164
[20]	Pfyffer GE, Welscher HM, Kissling P, et al. Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol, 1997, 35(2): 364-368. doi: 10.1128/jcm.35.2.364-368. doi: 10.1128/jcm.35.2.364-368.1997 pmid: 9003597
[21]	Somoskövi A, Magyar P. Comparison of the mycobacteria growth indicator tube with MB redox, Löwenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens. J Clin Microbiol, 1999, 37(5): 1366-1369. doi: 10.1128/JCM.37.5.1366-1369.1999. doi: 10.1128/JCM.37.5.1366-1369.1999 pmid: 10203488
[22]	Diacon AH, Dawson R, du Bois J, et al. Phase Ⅱ dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother, 2012, 56(6): 3027-3031. doi: 10.1128/AAC.06125-11. doi: 10.1128/AAC.06125-11 URL
[23]	Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis, 2011, 15(7): 949-954. doi: 10.5588/ijtld.10.0616. doi: 10.5588/ijtld.10.0616 pmid: 21682970
[24]	Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother, 2013, 57(5): 2199-2203. doi: 10.1128/AAC.02243-12. doi: 10.1128/AAC.02243-12 URL
[25]	Diacon AH, Maritz JS, Venter A, et al. Time toliquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect, 2012, 18(7): 711-717. doi: 10.1111/j.1469-0691.2011.03626.x. doi: 10.1111/j.1469-0691.2011.03626.x URL
[26]	Fenner F. The enumeration of viable tubercle bacilli by surface plate counts. Am Rev Tuberc, 1951, 64(4): 353-380. doi: 10.1164/art.1951.64.4.353. doi: 10.1164/art.1951.64.4.353
[27]	Walsh KF, McAulay K, Lee MH, et al. Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. Antimicrob Agents Chemother, 2020, 64(5): e01956-19. doi: 10.1128/AAC.01956-19. doi: 10.1128/AAC.01956-19
[28]	Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert Rev Anti Infect Ther, 2014, 12(2): 223-237. doi: 10.1586/14787210.2014.870884. doi: 10.1586/14787210.2014.870884 URL
[29]	Sirgel F, Venter A, Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J Antimicrob Chemother, 2001, 47(2): 177-182. doi: 10.1093/jac/47.2.177. doi: 10.1093/jac/47.2.177 URL
[30]	Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis, 1992, 73(1): 33-38. doi: 10.1016/0962-8479(92)90077-W. doi: 10.1016/0962-8479(92)90077-W URL
[31]	Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med, 1997, 156(3 Pt 1): 895-900. doi: 10.1164/ajrccm.156.3.9609132. doi: 10.1164/ajrccm.156.3.9609132 URL
[32]	Hafner R, Cohn JA, Wright DJ, et al. Early bactericidalactivity of isoniazid in pulmonary tuberculosis. Optimization of methodology.The DATRI008 Study Group. Am J Respir Crit Care Med, 1997, 156(3 Pt 1): 918-923. doi: 10.1164/ajrccm.156.3.9612016. doi: 10.1164/ajrccm.156.3.9612016 URL
[33]	Tessema B, Beer J, Emmrich F, et al. Rate ofrecovery of Mycobacterium tuberculosis from frozen acid-fast-bacillussmear-positive sputum samples subjected to long-term storage in Northwest Ethiopia. J Clin Microbiol, 2011, 49(7): 2557-2561. doi: 10.1128/JCM.00059-11. doi: 10.1128/JCM.00059-11 pmid: 21562105
[34]	Chambers HF, Kocagöz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis, 1998, 26(4): 874-877. doi: 10.1086/513945. doi: 10.1086/513945 pmid: 9564467
[35]	Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med, 2001, 1: 2. doi: 10.1186/1471-2466-1-2. doi: 10.1186/1471-2466-1-2 pmid: 11737875
[36]	Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infect Dis J, 2008, 2: 59-76. doi: 10.2174/1874279300802010059. doi: 10.2174/1874279300802010059 pmid: 23814629
[37]	Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle, 1985, 66(3): 219-225. doi: 10.1016/0041-3879(85)90040-6. doi: 10.1016/0041-3879(85)90040-6 pmid: 3931319
[38]	Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of rifabutin inpatients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother, 1993, 32(6): 867-875. doi: 10.1093/jac/32.6.867. doi: 10.1093/jac/32.6.867 URL
[39]	Kolwijck E, Mitchell M, Venter A, et al. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies. J Clin Microbiol, 2013, 51(4): 1094-1098. doi: 10.1128/JCM.02751-12. doi: 10.1128/JCM.02751-12 pmid: 23345289
[40]	Svensson RJ, Svensson EM, Aarnoutse RE, et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. J Infect Dis, 2018, 218(6): 991-999. doi: 10.1093/infdis/jiy242. doi: 10.1093/infdis/jiy242 pmid: 29718390
[41]	Botha FJ, Sirgel FA, Parkin DP, et al. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J, 1996, 86(2): 155-158.
[42]	Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis, 1993, 148(6 Pt 1): 1547-1551. doi: 10.1164/ajrccm/148.6_Pt_1.1547. doi: 10.1164/ajrccm/148.6_Pt_1.1547 URL